- Home
- POAI vs PMCB Comparison
POAI vs PMCB Comparison
Compare POAI & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- PMCB
- Stock Information
- Founded
- POAI 2002
- PMCB 1996
- Country
- POAI United States
- PMCB United States
- Employees
- POAI N/A
- PMCB N/A
- Industry
- POAI Industrial Specialties
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- POAI Health Care
- PMCB Health Care
- Exchange
- POAI Nasdaq
- PMCB Nasdaq
- Market Cap
- POAI 8.9M
- PMCB 7.3M
- IPO Year
- POAI N/A
- PMCB N/A
- Fundamental
- Price
- POAI $0.80
- PMCB $1.11
- Analyst Decision
- POAI Hold
- PMCB
- Analyst Count
- POAI 1
- PMCB 0
- Target Price
- POAI N/A
- PMCB N/A
- AVG Volume (30 Days)
- POAI 164.4K
- PMCB 12.1K
- Earning Date
- POAI 08-12-2025
- PMCB 08-12-2025
- Dividend Yield
- POAI N/A
- PMCB N/A
- EPS Growth
- POAI N/A
- PMCB N/A
- EPS
- POAI N/A
- PMCB 1.29
- Revenue
- POAI $1,729,269.00
- PMCB N/A
- Revenue This Year
- POAI $486.27
- PMCB N/A
- Revenue Next Year
- POAI $65.50
- PMCB N/A
- P/E Ratio
- POAI N/A
- PMCB $0.85
- Revenue Growth
- POAI 24.17
- PMCB N/A
- 52 Week Low
- POAI $0.55
- PMCB $1.00
- 52 Week High
- POAI $3.06
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- POAI 32.97
- PMCB 51.40
- Support Level
- POAI $0.73
- PMCB $1.06
- Resistance Level
- POAI $0.86
- PMCB $1.15
- Average True Range (ATR)
- POAI 0.05
- PMCB 0.05
- MACD
- POAI -0.00
- PMCB 0.01
- Stochastic Oscillator
- POAI 30.59
- PMCB 60.00
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.